Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I ascending-dose AZD3514 in metastatic castration-resistant prostate cancer
NL-OMON34099Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD3514 in castration-resistant prostate cancer (CRPC) and prostate cancer (PCa), sponsored by AstraZeneca. Primary endpoint: Safety and tolerability of AZD3514. Started Aug 2010; status: active, not recruiting.
02
Drugs
AZD3514
03
Conditions
castration-resistant prostate cancer (CRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON34099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34099.